DIA Appoints Co-Chairs for 2016 EuroMeeting in Hamburg
The congress will be held at the Congress Center Hamburg (CCH) in Germany on 6 to 8 April 2016. For the first time, it will feature one or more sessions on medical writing.
Karl Broich, President of the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) in Germany, and Kemal Malik, a member of the board of management at Bayer AG in Germany, will be the co-chairs of the 28th Drug Information Association (DIA) EuroMeeting.
The congress will be held at the Congress Center Hamburg (CCH) in Germany on 6 to 8 April 2016. For the first time, it will feature one or more sessions on medical writing.
The call for abstracts for presentations, full sessions and tutorials is open until 29 June. Applicants may submit more than one abstract, and they should cover innovation, clinical research, clinical trials, regulatory science, medical affairs, eHealth/big data, pharmacovigilance, lifecycle benefit/risk management, availability of medicinal products, globalization, medical devices and combination products, and health tech assessment.
According to a statement on the DIA web site, the main aim of the 2016 EuroMeeting will be “to provide a platform for experts from all relevant disciplines within the entire healthcare development and access process to debate and find solutions to some of the most pertinent challenges faced in an ever-evolving healthcare system - including the need to drive innovation.”
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
